1. World Health Organization. Global tuberculosis report 2018. Geneva: WHO; 2018. Available at:
  2. Majumdar SS, Marais BJ, Denholm JT, Britton WJ. Drug-resistant tuberculosis: collaborative regional leadership required. Med J Aust 2014;200:241–2.
  3. Toms C, Stapledon R, Douglas P, National Tuberculosis Advisory Committee, for the Communicable Diseases Network Australia, Australian Mycobacterium Reference Laboratory Network, (null), et al. Tuberculosis notifications in Australia, 2014. Commun Dis Intell Q Rep. 2017;41(3):E247–63.
  4. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, WHO; 2018. Available at:
  5. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. European Respiratory Journal. 2019 Sep 12;54(3):1900655–14.
  6. Dale KD, Trauer JMC, Dodd PJ, et al. Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia. Eur Respir J 2018; 52: 1801218
  7. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016 Oct 27;2(1):845–23.
  8. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of ‘latent tuberculosis infection’ in patients living with HIV infection. Clin Dev Immunol 2011;2011:1–9
  9. Dodd CE, Schlesinger LS. New concepts in understanding latent tuberculosis.Curr Opin Infect Dis. 2017 Jun;30(3):316-321
  10. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015 May 28;372(22):2127–35.
  11. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.
  12. Sonnenberg, J. R. Glynn, K. Fielding, J. Murray, P. Godfrey- Fausselt, and S. Shearer, “How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners,” Journal of Infectious Diseases, vol. 191, no. 2, pp. 150–158, 2005
  13. C. B. Holmes, R. Wood, M. Badri et al., “CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 4, pp. 464–469, 2006.
  14. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35
  15. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21(11):1441-8
  16. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007;21(6):713-9
  17. Ellis, P. K., Martin, W. J., & Dodd, P. J. (2017). CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ5, e4165. doi:10.7717/peerj.4165
  18. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500
  19. Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med 2013; 11: 253
  20. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-m7
  21. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-m7
  22. N. Benito, A. Moreno, J.M. Miro, A. Torres. Pulmonary infections in HIV-infected patients: an update in the 21st century.Eur Respir J, 39 (2012), pp. 730-745
  23. F. A. Post, R. Wood, and G. P. Pillay, “Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count,” Tubercle and Lung Disease, vol. 76, no. 6, pp. 518–521, 1995,
  24. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423
  25. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326(4):231-235
  26. Nachega J, Maartens G. Chapter 51. Clinical aspects of tuberculosis in HIV-infected adults. In: Schaaf HS, Zumla A editors Tuberculosis: A Comprehensive Clinical Reference, Philadelphia: Saunders; 2009
  27. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007;369(9578): 2042–9.
  28. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. The lancet Respiratory medicine. 2015 Dec;3(12):963–72.
  29. Rapid implementation of the Xpert MTB/RIF diagnostic test. World Health Organization, Geneva. (WHO/HTM/TB/2011.2).
  30. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013;1:CD009593–3. Updated 2014 Jan 21;1:CD009593
  31. Horne  DJ, Kohli  M, Zifodya JS, Schiller I, Dendukuri  N, Tollefson  D et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub4.
  32. World Health Organization. The use of Xpert MTB/RIF assay for the detection of pulmonary and extrapulomnary tuberculosis and rifampicin resistance in adults and children. Expert group meeting. October 2013. 2013%20%20Pre%20publication%20FINAL.pdf
  33. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 Jan;18(1):76-84.
  34. Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clinical Microbiology and Infection. 2019 Mar;:1–7.
  35. Lawn SDS, Kerkhoff ADA, Vogt MM, Wood RR. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012;12:201–9.
  36. Peter JG, Zijenah LS, Chanda D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016; 387: 1187–97.
  37. Broger T, Sossen B, Toit du E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. The Lancet Infectious Diseases. 2019 Aug;19(8):852–61.
  38. Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nature Reviews Microbiology. 2019 Jun 17;17(9):533–45.
  39. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva: World Health Organization; 2018 (WHO/CDS/TB/2018.19). Available at:
  40. Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tubercle and Lung Disease, vol. 76, no. 6, pp. 518–521, 1995.
  41. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-m7 
  42. World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. WHO/HTM/ TB/2013.04. Geneva, Switzerland: WHO, 2013. Available at:
  43. Winter JR, Adamu AL, Gupta RK, Stagg HR, Delpech V, Abubakar I. Tuberculosis infection and disease in people living with HIV in countries with low tuberculosis incidence. Int J Tuberc Lung Dis. 2018 Jul 1;22(7):713–22.
  44. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma J: An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010, 362:707–716
  45. World Health Organization. Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. WHO/HTM/ TB/2016.20. Geneva, Switzerland: WHO, 2016. Available at:
  46. Qin ZZ, Sander MS, Rai B, Titahong CN, Sudrungrot S, Laah SN, et al. Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems. Sci Rep. 2019 Oct 18;9(1):85–10.
  47. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferonrelease assays for incidentactive tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45–55
  48. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr. 2011 Mar;56(3):230–8.
  49. Stock D, National Tuberculosis Advisory Committee. National position statement for the management of latent tuberculosis infection. Commun Dis Intell Q Rep. 2017 Sep 1;41(3):E204–8.
  50. National Tuberculosis Advisory Committee. Position statement on interferon release assays in the detection of latent tuberculosis infection. Commun Dis Intell 2012;36:125-31.Available at:
  51. ASHM Antiretroviral guidelines: US DHHS guidelines with Australian commentary. Mycobacterium Tuberculosis Disease with HIV Co-infection. (Last updated:14/07/2016). Available at:
  52. Denholm J, Eisen D, Fox G, McBryde E, Street A. Management of Tuberculosis: A guide for clinicians. 2017.
  53. British HIV Association. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2018 (2019 interim update). Available at:
  54. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at
  55. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, Switzerland: WHO, 2011. Available at:
  56. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Sep 12;63(7):853–67.
  57. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9
  58. Furin J, Cox H, Pai M. Tuberculosis. The Lancet. 2019 Apr;393(10181):1642–56.
  59. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W: Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta- analysis. PLoS Med 2009, 6:e1000146
  60. WHO. WHO consolidated guidelines drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. Available at:
  61. Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2018 Aug 9.
  62. Nunn AJ, Phillips PPJ, Meredith SK, CHIANG C-Y, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 Mar 28;380(13):1201–13.
  63. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet. 2018 Sep;392(10150):821–34.
  64. Trebucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis.2018;22(1):17-25.
  65. Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr. Management of drug-resistant tuberculosis. The Lancet. 2019 Sep;394(10202):953–66.
  66. Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. (2009) Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLoS ONE 4(5): e5575.
  67. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167:1472–1477
  68. Grinsztejn B, De Castro N, Arnold V et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.